CDC: School children may need four immunizations this fall
NEW YORK School children may need as many as four immunizations against both seasonal flu and the novel H1N1 virus this year, Centers for Disease Control and Prevention officials told clinicians Wednesday, according to published reports.
That regimen includes an initial shot and booster of both vaccines for children. Most everyone else will only need to get their regular seasonal shot and two shots for the novel H1N1 vaccine, when one is available.
Five manufacturers are currently producing vaccines against the pandemic H1N1 swine flu virus — CSL Biotherapies, GlaxoSmithKline, Medimmune, Novartis and Sanofi Pasteur.
The five manufacturers are expected to deliver between 40 million and 160 million doses of vaccine by October. The regular seasonal flu vaccine supply will be ready much earlier than usual, possibly as soon as late August.
According to CDC officials, pandemic flu shots will be allocated among states based on their population.
Purdue Products unveils reformulated line of laxatives
STAMFORD, Conn. Purdue Products recently unveiled its reformulated line of Senokot branded laxatives — the tablets are not chemically processed and the primary ingredient is the deseeded pod of the senna plant.
“We’ve always been proud of the fact that Senokot Tablets are such a trusted laxative brand,” stated Charlene Bailey, director, product management, Purdue Products. “But we’re really excited to give consumers something new – especially at a time when interest is so high in natural products.” The new Senokot Tablets will be available in pharmacies nationwide in early October.
Purdue will support the introduction with a comprehensive media plan that includes national television advertising, retail account programs, coupons and rebates. In addition, the contemporary design for the brand will stand out on-shelf while reinforcing Senokot as a natural choice for today’s health-minded consumers.
GNC releases clinical results of neuromuscular fatigue treatment
LAS VEGAS GNC on Monday released clinical results for its nitric oxide product Amplified Maxertion N.O. — demonstrating a delay in the onset of neuromuscular fatigue — at the National Strength and Conditioning Association conference.
GNC’s Amplified Maxertion N.O. was shown to increase power output at the onset of neuromuscular fatigue by an average of 20% and improve physical performance by helping athletes push past their normal point of exhaustion.
“This is truly groundbreaking research that has resulted in the delivery of a truly novel and clinically-validated [sports nutrition] product to the industry,” stated Guru Ramanathan, SVP technology and product innovation for GNC. “Using advanced technology and ingredients, this is the first nitric oxide enhancing product to demonstrate significant athletic performance effects that are relevant and meaningful to all types of athletes.”
Amplified Maxertion N.O. is part of a comprehensive line of eight new advanced muscle performance and sports nutrition products from GNC. The entire Pro Performance AMP line was designed to suit the needs of a wide range of dedicated athletes, from the weekend warrior to the ultra competitive athlete.